Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

Earnings Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0 18 per share, significantly worse than the Zacks Consensus Estimate of a loss of$ 0 01, representing an earnings surprise of -1,700% [1] - The company's loss per share improved from $0 20 a year ago, showing a year-over-year improvement [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Revenue Performance - Kiniksa Pharmaceuticals posted revenues of$ 112 21 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1 77% [2] - This represents a significant increase from year-ago revenues of $67 05 million [2] - The company has topped consensus revenue estimates four times over the last four quarters [2] Stock Performance - Kiniksa Pharmaceuticals shares have added about 57 3% since the beginning of the year, outperforming the S&P 500's gain of 22 1% [3] - The stock's immediate price movement will depend on management's commentary on the earnings call [3] Earnings Outlook - The current consensus EPS estimate is$ 0 02 on $119 26 million in revenues for the coming quarter and -$ 0 29 on $418 02 million in revenues for the current fiscal year [7] - The estimate revisions trend for Kiniksa Pharmaceuticals is favorable, translating into a Zacks Rank 2 (Buy) [6] Industry Context - Kiniksa Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 30% of the 250 plus Zacks industries [8] - The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8] Peer Comparison - Affimed N V, another stock from the same industry, is expected to post a quarterly loss of$ 1 14 per share, representing a year-over-year improvement of +32 9% [9] - Affimed N V's revenues are expected to be $1 41 million, down 34 4% from the year-ago quarter [9]